Here are nearly
300 medicines in clinical development to treat cardiovascular disease. This new
research report examines in detail the key areas of the cardiovascular (CV)
market, gathering inside opinion of cardiologists, to highlight the dynamic
changes that are underway in this multibillion dollar marketplace.
To
Read The Complete Report with TOC :-
Successful
players will, necessarily, need to cannibalise their existing cardiovascular
franchises in order to limit the impact of generic erosion when their patents
expire, whilst at the same time investing in alternative therapies with better,
more efficacious outcomes. This is a significant challenge given the high
barrier to entry and unmet clinical needs. Not only is cardiovascular disease a
“Silent Killer”, it is also a commercial time bomb where the risk/reward ratio
for any company willing to participate needs to be carefully considered.
This report
provides you with a systematic appraisal into the current and future CV market,
including...
A detailed review
of the leading brands and how they are being positioned in the market, in
addition to the potential impact of generics
- Assessment of key products in development, identifying ‘Ones to Watch’ in late-stage clinical development where proof of concept data has been established
- Review of products that are ‘Waiting in the Wings’ in early-stage clinical development where Point-of-Care data is being gathered
- Analysis of the potential of ‘Long Shots’ which represent new and innovative products where the scientific rationale has yet to be fully tested
- Antilipidemics
The lowering of
‘bad cholesterol’ or low-density lipoprotein cholesterol (LDL-C) and
triglycerides (TGs) has been shown to reduce the chance of a heart attack and
death in people who have an elevated risk of developing heart disease or who
already have heart disease. Several drug classes are currently available to
treat a range of lipid disorders; each has a different mechanism of action,
safety profile and impact on blood lipid profiles to different degrees.
To Buy a Copy Of This Report:-
Key drugs covered
by the report include
- Leading brands - Lipitor (Pfizer), Crestor (AstraZeneca), Livalo (Kowa and Partners), etc...
- Recent generics - Atorvastatin, etc...
- Ones to watch - Alirocumab (Sanofi/Regeneron Pharmaceuticals), AMG 145 (Amgen), Anacetrapid (Merck & Co), etc...
- Waiting in the wings - RG 7652 (Roche), RN-316 (Pfizer), DRL-17822 (Dr Reddy), etc...
- Long shots - ALN PCS (Alnylam/The Medicine Company), etc...
- Just some of the key questions answered include
- Why are statins the gold stand in lipid lowering therapies and which is the most effective at lowering LDL-C?
- Will AstraZeneca’s Crestor win its fight for supremacy before generic rosuvastatin reaches the market?
- Why are PCSK9 inhibitors important to cardiologists and which drugs are leading the field?
- Kynamro approved in the US but not in Europe… what next?
- What new HDL-C modulating therapies are in development?
- What new products are in development from BMS/Simcere; Dr Reddy and DezimaPharma?
Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948
No comments:
Post a Comment